Immunogenicity and safety of a varicella vaccine (Okavax™) and a trivalent measles, mumps, and rubella vaccine (Trimovax™) administered concomitantly in healthy Filipino children 12-24 months old

American Journal of Tropical Medicine and Hygiene

Volumn 70, Issue 3, 2004, Pages 273-277

  Gatchalian, Salvacion ^a   Tabora, Charissa ^a   Bermal, Nancy ^a   Leboulleux, Didier ^b   Desauziers, Eric ^c  

^a Department of Dermatology   (Philippines)

^b DCH Commercial Centre   (Hong Kong)

^c SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; MEASLES MUMPS RUBELLA VACCINE; OKAVAX; VARICELLA BIKEN; VARICELLA ZOSTER VACCINE;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GEOMETRY; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; INFANT; MALE; NORMAL HUMAN; OPEN STUDY; PAROTID GLAND DISEASE; PHILIPPINES; PRURITUS; PURPURA; RASH; REACTION ANALYSIS; SEROCONVERSION; VACCINATION;

CHICKENPOX VACCINE; FEMALE; HUMANS; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE; VACCINATION;

DNA VIRUSES; PURPURA;

EID: 1642393316     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Redd S, Markowitz L, Katz S, 1999. Measles vaccine. Plotkin SA, Orenstein WA, eds. Vaccines. Third edition. Philadelphia: W. B. Saunders, 222-250.
2. Galazka AM, Robertson SE, Kraigher A, 1999. Mumps and mumps vaccine: a global review. Bull World Health Organ 77: 3-14.
3. Centers for Disease Control and Prevention, 1998. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 47: 1-57.
4. Cutts FT, Henderson RH, Clements CJ, Chen RT, Patriarca PA, 1991. Principles of measles control. Bull World Health Organ 69: 1-7.
5. World Health Organization, 1995. Expanded program of immunization, 1995. Immunization schedules in the WHO European region. Wkly Epidemiol Rec 70: 221-227.
6. Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, Cantell K, 1994. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 331: 1397-1402.
7. Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen OP, 2000. Mumps and rubella eliminated from Finland. JAMA 284: 2643-2647.
8. Centers for Disease Control and Prevention, 1996. Prevention of varicella: recommendations of the Advisory Committee On Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 45: 1-25.
9. Takahashi M, 2001. 25 years experience with the Biken Oka strain varicella vaccine: a clinical overview. Paediatr Drugs 3: 285-292.
10. White CJ, Kuter BJ, Hildebrand CS, Isganitis KL, Matthews H, Miller WJ, Provost PJ, Ellis RW, Gerety RJ, Calandra GB, 1991. Varicella vaccine (Varivax) in healthy children and adolescents: results from clinical trails, 1987 to 1989. Pediatrics 87: 604-610.
11. Meurice F, De Bouver J-L, Vandevoorde D, Woods S, Bogaerts H, 1996. Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children. J Infect Dis 174 (suppl 3): S324-S329.
12. Arvin A, 2001. Varicella vaccine - the first six years. N Engl J Med 344: 1007-1009.
13. Vasquez M, LaRussa PS, Gersbon AA, Steinberg SP, Freudigman K, Shapiro ED, 2001. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 344: 955-960.
14. National Vaccine Advisory Committee, 1991. The measles epidemic. The problems, barriers and recommendations. JAMA 266: 1547-1552.
15. World Health Organization, 1999. Measles. Progress towards global control and regional elimination. 1998-1999. Wkly Epidemiol Rec 50: 429-439.
16. Arguedas AG, Deveikis AA, Marks MI, 1991. Measles. Am J Infect Control 19: 290-298.
17. Centers for Disease Control and Prevention, 1989. Mumps-United States. 1985-1988. MMWR Morb Mortal Wkly Rep 38: 101-105.
18. Centers for Disease Control and Prevention, 1991. Increase in rubella and congenital rubella syndrome-United States, 1988-1990. MMWR Morb Mortal Wkly Rep 40: 93-99.
19. Roussey M, Senecal J, Bentejac M-C, Xueref C, 1986. La vaccination triple ROR. Immunol Med 15: 9-15.
20. Clerc M, 1986. Etude clinique du vaccin ROR triple associé a virus vivants atténués Contre la rougeole, les oreillons et la rubéole. Immunol Med 15: 16-18.
21. Robertson CM, Bennett VJ, Jefferson N, Mayon-White RT, 1988. Serological evaluation of measles, mumps, and rubella vaccine. Arch Dis Child 63: 612-616.
22. Dunlop JM, RaiChoudhury K, Roberts JS, Bryett KA, 1989. An evaluation of measles, mumps and rubella vaccine in a population of Yorkshire infants. Public Health Rep 103: 331-335.
23. Samoilovich EO, Kapustik LA, Feldman EV, Yermolovich MA, Svirchevskaya AJ, Zakharenko DF, Fletcher MA, Titov LP, 2000. The immunogenicity and reactogenicity of the trivalent vaccine. Trimovax™, indicated for prevention of measles, mumps, and rubella, in 12-month-old children in Belarus. Cent Eur J Public Health 3: 160-163.
24. Osaki T, Nishimura N, Kajita Y, 2000. Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects: 10-year survey at pediatric clinic. Vaccine 18: 2375-2380.
25. Just M, Berger R, Just V, 1986. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine. Dev Biol Stand 65: 85-88.
26. Berger R, Just M, 1988. Interference between strains in live virus vaccines. II: Combined vaccination with varicella and measles-mumps-rubella vaccines. J Biol Stand 16: 275-279.
27. Vesikari T, Öhrling A, Baer M, Delem A, Bogaerts H, Andre FE, 1991. Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children. Acta Paediatr Scand 80: 1051-1057.
28. IIV) in healthy children. J Infect Dis 173: 731-734.
29. White CJ, Stinson D, Staehle B, Cho I, Matthews H, Ngai A, Keller P, Eiden J, Kuter B, 1997. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Clin Infect Dis 24: 925-931.
30. Clements DA, 1996. Modified varicella-like syndrome. Infect Dis Clin North Am 10: 617-629.
31. White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, Patterson CM, Capra A, Miller WJ, Krah DL, Provost PJ, Ellis RW, Calandra GB, 1992. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 11: 19-23.
32. Peltola H, Heinonen OP, 1986. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-bind placebo-controlled trial in twins. Lancet 1: 939-942.
33. Decker MD, Edwards KM, 1999. Combination Vaccines. Plotkin SA, Orenstein WA, eds. Vaccines. Third edition. Philadelphia: W. B. Saunders, 508-518.